Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-04193-6 , published online 3 February 2026. In the version of the article initially published, there were errors in the NfL data in Fig.
2 , Table 2 and Extended Data Fig. 4 .
The original figures and table are available for comparison in the Supplementary information accompanying this amendment. In the Results, in the “Part B cohort with infantile-onset SMA: neurodegeneration” section, the text “…compared with the ENDEAR matched sham group (30% reduction)” has been corrected to “…compared with the ENDEAR matched sham group (32% reduction)”, and “nominally significant P = 0.0050” has been corrected to “nominally significant P = 0.0075”.
In the “Part B cohort with later-onset SMA: neurodegeneration” section, the text “nominally significant P = 0.0495” has been corrected to “nominally significant P = 0.0047”. These corrections have been made to the HTML and PDF versions of the article.
Peng Sun, Angela D.
Nature Medicine published a clinical update in Research Highlights on 23 Apr 2026.
The item focuses on Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Review the original article for the full source wording and details.